NeoGenomics, Inc. Q4 FY2025 earnings call

Anthony Zook discussed Q4 highlights like record revenues, progress on NGS and MRD initiatives. RADAR ST to launch end of month, PANTRASER portfolio growth. Jeff Sherman discussed Q4 and full year financials. Abhishek Jain introduced 2026 guidance. Management emphasized commercial organization investment, LIMS rollout for efficiency.

Fourth quarter total revenue was $190 million, +11% YOY. Clinical revenue increased 16% YOY. NGS revenue grew 23% in Q4. Full year total revenue $727 million, +10% YOY. Clinical revenue +15% YOY. Nonclinical revenue declined 24% for the year.

2026 revenue expected $793,000,000 to $801,000,000. Adjusted EBITDA $55 million to $57,000,000, +27% to 31% YOY. Quarterly cadence with growth expected in later quarters.

Forward-looking statements subject to risks of actual results differing from expectations, as per SEC disclosures.

Q: Details on RADAR ST launch, sales reps, PANTRASER liquid.

A: RADAR ST launching end of month, sales reps expanding for head and neck etc.

Q: Clinical volume impact of exiting low value business.

A: AUP growth expected, focusing on high margin tests.

Q: Guidance reconciling core clinical growth.

A: Clinical growth expected double-digit, prudent guide considering LBX approval.

Q: LIMS rollout impact.

A: LIMS migration modality by modality, benefits in later years.

Q: Pharma ordering and RADAR ST impact.

A: Modest pharma erosion, RADAR ST a growth driver.

Q: ASP growth and reimbursement.

A: NGS, pricing increases, managed care impact AUP growth.

Q: Salesforce productivity and PANTRASER liquid.

A: Salesforce productive, LBX pending MolDX approval.